Previous 10 | Next 10 |
Sunesis Pharmaceuticals (NASDAQ: SNSS ): Q4 GAAP EPS of -$0.16 beats by $0.03 . More news on: Sunesis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SOUTH SAN FRANCISCO, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and year ended December 31, 2018. Loss from operations for the three months and year ended December 31, 2018 was $5.8 million ...
SOUTH SAN FRANCISCO, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will participate in three upcoming investor conferences in March: Event: Cowen and Company 39 th Annual Health Care Conference Dat...
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Thursday, March 7 th , 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter ...
Recently, the ArQule’s lead candidate, derazantinib, showed positive preliminary action from a Phase 2 liver cancer study. In addition, ArQule reported that partner Basilea Pharmaceutica (OTC: BPMUF ) will team up with Roche (OTCQX: RHHBY ) to assess the combination of derazantinib,...
- 50 mg Cohort Completed - - Clinical Update Expected in the Second Quarter of 2019 - SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company has opened the 100 mg cohort in the Phase 1b/2 trial of...
Oppenheimer says small- to mid-cap biotech stocks could have more downside risk going into the new year after this quarter's pullback while the historically low valuations for large-cap companies could reach the lowest point. More news on: Regeneron Pharmaceuticals, Inc., Alexion Pharmaceu...
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chroni...
Sunesis Pharmaceuticals, Inc. (SNSS) Q3 2018 Earnings Conference Call November 05, 2018, 16:30 ET Executives William Quinn - SVP, Finance & Corporate Development and CFO Dayton Misfeldt - Interim CEO & Director Judith Fox - Chief Scientific Officer Analysts Marc Fra...
Sunesis Pharmaceuticals (NASDAQ: SNSS ): Q3 GAAP EPS of -$0.18 beats by $0.01. More news on: Sunesis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Viracta Therapeutics Inc Com Company Name:
SNSS Stock Symbol:
NASDAQ Market:
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement Shares of Viracta to commence trading on the Nasdaq Global Select Market on February 25, 2021 under ticker symbol 'VIRX' Cash and cash equivalents of over $120 million as...
There’s Blood In The Streets, But Opportunity Could Be Presenting Itself With Penny Stocks What’s your strategy for finding the best penny stocks to buy ? At the top of my mind, there are a few things to look at. One of them is industry sentiment. Several industries ha...
Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma Resulting patent to extend Viracta's intellectual property protection into at least 20...